<DOC>
	<DOCNO>NCT01659034</DOCNO>
	<brief_summary>The purpose study evaluate safety reduction thienopyridine treatment period 3 month implantation Cobalt-Chromium everolimus-eluting Stents .</brief_summary>
	<brief_title>Short Optimal Duration Dual Antiplatelet Therapy Study</brief_title>
	<detailed_description>`` Thienopyridine antiplatelet agent markedly inhibit incidence stent thrombosis , combine aspirin 1 month implantation bare-metal stent ( BMS ) . On hand , combination aspirin thienopyridine ( dual antiplatelet therapy : DAPT ) 1 year drug-eluting stent ( DES ) implantation frequently use prevent late stent thrombosis current clinical practice . In RESET study , carry clinical practice Japan , DAPT perform least 1 year 90 % patient . However , report show long-term thienopyridine treatment least 1 year reduces incidence serious cardiovascular event , large-scale observational study small-scale randomized comparative study demonstrate thienopyridine treatment 6 month least 12 month reduce incidence serious cardiovascular event . These result suggest optimal duration DAPT DES implantation may shorter 6 month . With respect Everolimus-eluting stent ( EES ) , widely use DES Japan , associate significantly low incidence early late stent thrombosis compare first-generation DES BMS large-scale observational study randomize comparative study meta-analyses . Considering long-term DAPT obviously increase hemorrhagic complication compare Aspirin monotherapy , desirable reduce duration DAPT far possible , long-term DAPT effective inhibiting incidence serious cardiovascular event . Moreover , long-term DAPT enormously increase medical expense . In study , plan exploratory multicenter study evaluate incidence cardiovascular event bleed event 12 month stent implantation use EES ( XIENCE Primeâ„¢ ) , associate low risk stent thrombosis , thienopyridine therapy discontinue 3 month surgery .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patients receive PCI use everolimuseluting cobaltchromium stent Patients implant drugeluting stent everolimuseluting cobaltchromium stent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Anti-platelet therapy</keyword>
</DOC>